SCHEMBL25548889

SCHEMBL25548889

CC(C)(C)C[C@H](NC(=O)c1ccc2ccccc2c1OCc1ccc(S(F)(F)F)cc1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 3/20 0.48
▸ GRN P28799 2/20 0.39
▸ SORT1 Q99523 2/20 0.39
▸ PTPN1 P18031 2/20 0.38
▸ KIFC1 Q9BW19 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ MME P08473 1/20 0.36
▸ ACE P12821 1/20 0.36
▸ CPA1 P15085 1/20 0.36
▸ ACE2 Q9BYF1 1/20 0.36
▸ ELANE P08246 4/20 0.36
▸ CA2 P00918 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ FNTA P49354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460786 0.91 CXCR2 (0.46) CXCR2GRNSORT1PTPN1LMNA
SCHEMBL23460787 0.91 CXCR2 (0.46) CXCR2GRNSORT1PTPN1LMNA
SCHEMBL23460974 0.90 CXCR2 (0.48) CXCR2GRNSORT1PTPN1KIFC1
SCHEMBL23460971 0.90 CXCR2 (0.48) CXCR2GRNSORT1PTPN1KIFC1
SCHEMBL25549056 0.89 CXCR2 (0.46) CXCR2PTPN1KIFC1LMNAELANE
SCHEMBL23460897 0.88 CXCR2 (0.62) CXCR2GRNSORT1PTPN1KIFC1
SCHEMBL23460899 0.88 CXCR2 (0.62) CXCR2GRNSORT1PTPN1KIFC1
SCHEMBL25549059 0.87 CXCR2 (0.48) CXCR2GRNSORT1PTPN1KIFC1
SCHEMBL25560308 0.87 CXCR2 (0.49) CXCR2LMNACA2KDM4EALDH1A1
SCHEMBL25549526 0.87 CXCR2 (0.49) CXCR2LMNACA2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885GRN 4157/4885SORT1 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback